Detalhe da pesquisa
1.
Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.
Lancet Oncol
; 14(1): 72-80, 2013 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-23246022